Improving the cost-effectiveness of cardiovascular disease prevention in Australia

A modelling study

Bibliographic Data

ID15364015
AuthorsLinda J Cobiac, Linda Cobiac (0000-0002-2271-6494, The University of Queensland, corresponding author), Anne Magnus (0000-0002-1165-8161, Deakin University), Jan J Barendregt (The University of Queensland), Rob Carter (0000-0002-1586-5619, Deakin University), Theo Vos (0000-0002-5690-5365, The University of Queensland)
Year2012
Volume12
Issue1
Pages398-398
Publication date2012-06-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueBMC Public Health (JOURNAL)
Journal identifiersISSN: 1471-2458 • E-ISSN: 1471-2458
PublisherBioMed Central (PUBLISHER • GB)
DOI10.1186/1471-2458-12-398
PMID22657090
PMCIDPMC3560211
OpenAlexW2028835416
LanguageEN
Citations received4
References cited30

Changing to absolute risk-based cardiovascular disease prevention is highly recommended for reducing health sector spending, but the Australian Government must also consider measures to reduce the cost of statin drugs, over and above the legislated price cuts of November 2010

Absolute risk reduction · Blood pressure · Cost effectiveness · Disease · Environmental health · Intensive care medicine · Pathology · Polypill · Population · Public health · Risk analysis (engineering · Risk assessment · Stroke (engine · Blood Pressure and Hypertension Studies · Health Systems, Economic Evaluations, Quality of Life · Lipoproteins and Cardiovascular Health · Medicine · Epidemiology · Internal Medicine

Tools

Open DOISci-HubOpen Access